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INTRODUCTION: Breast cancer is a heterogeneous condition, with variants which are less common but
still very well deﬁned by the World Health Organization (WHO) classiﬁcation. With the small number of
cases each year large trials are difﬁcult to perform. This series aims to discuss the rare breastmalignancies
encountered within a breast department and the evidence based approached to their management.
METHOD: Literature search of electronic databases via PubMed and the search engines Google/Google
Scholar were used. Emphasis on keywords: breast cancer and the type of histology used to limit search.
Searches were screened and those articles suitable had full text versions retrieved. The references to all
retrieved texts were searched for further relevant studies.
CONCLUSION: Due to the rarity of some of these breast cancers, systematic evaluation of patient with
detailed histopathologywill aid accurate diagnosis andmanagement. The series hopes to add the existing
understanding of this small percentage of cases.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).
1. Introduction
Breast cancer is the commonest cancer in UK [1] and one-third
of all newcases of cancer inwomen [2]with about 55,000newdiag-
noses made annually. A large majority of breast cancers (60%) are
invasive ductal carcinoma [3]which is often described as no special
type with about 10% being invasive lobular carcinoma. However as
a heterogeneous condition, there are other variants which are less
common but still very well deﬁned by the World Health Organiza-
tion (WHO) classiﬁcation [4]. With the small number of cases each
year large trials are difﬁcult to perform.
This series aims to discuss the rare breast malignancies
encountered within a breast department and the evidence based
approached to their management.
2. Lymphoma of the breast
2.1. Case reports 1
A68yearold ladywas recalled frombreast screening for apoorly
deﬁned opacity in her left lower breast. Mammogram showed a
2 cm lesion and an FNA was reported as C5 suspicious for lym-
phoma. She underwent a core biopsy of the breast lump. This
suggestedaBcellmature follicular lymphoma. Lymphoidcellswere
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B cells expressing CD20 and CD 79a. Reactive T cells CD2, CD3 and
DC5 were all positive surrounding the follicles. CD5 restricted to
T cells. Lymphoid cells were cyclin D1-negative. Follicular cells
expressed CD10, Bcl6 and BCl2. In situ hybridisation studies for
kappa and lambda light chains show scattered plasma cells with
a polytypic pattern of light chain expression. She underwent bone
marrow biopsy, which showed no evidence of marrow inﬁltration
by follicular lymphoma.
Treatment: She went on to have 8 courses of R-CHOP. After
her 5th cycle the vincristine was changed to vinblastine to help
with neuropathy. An interval CT showed reduction in size of known
lesion in the left breast indicating response to treatment. She was
maintained on Rituximab on 2 monthly basis for 2 years.
She remained follow up suggesting no recurrence after 2 years
of diagnosis Fig. 1.
2.2. Case reports 2
A 76 year old lady presented with a 9 week history of a rapidly
enlarging lump on the sternal notch. On examination there was a
3 cm by 3 cm ﬁrm lump palpable on the sternum. Breast examina-
tion was unremarkable. Mammogram showed no abnormality in
the breast but ultrasound of the mass showed a soft tissue lesion.
FNA came back as C4 suspicious of lymphoma and core biopsy
showed features suggesting of plasmablastic lymphoma. Staging
CT scan conﬁrmed the presternal mass was inﬁltrating the pec-
toralis major muscles with no deﬁnite bony destruction but high
attenuation in themarrow implyingmarrow inﬁltration. Therewas
http://dx.doi.org/10.1016/j.ijscr.2015.03.010
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/4.0/).
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Fig. 1. Immunohistochemistry sample of lymphoma of breast.
no signiﬁcant lymphadenopathyelsewhere and spleenwasnormal.
Bone marrow aspirate and trephine from the posterior iliac crest
had no features to suggest myeloma or marrow inﬁltration with
lymphoma.
A repeat CT 3 months post diagnosis and following chemother-
apy showed that the soft tissuemasswas completely resolvedwith
no residuum, but there was diffuse ground glass change in both
lungs suggesting drug toxicity, intercurrent infection or diffuse
lymphoma in the lungs.
2.3. Case reports 3
A 49 year old ladywas recalled from screening for an abnormal-
ity detected in the left breast. Ultrasound showed a 21mm mass.
FNA was C1 and core biopsy was reported as lymphoid tissue with
suspicion of lymphomaB3. Incidentally, she also had a 2 cmby2cm
ﬁrm lump on the right forearm ulnar aspect, ﬁrmly adherent to
underlying structures. The breast lesion was completely excised
for histology. Immunohistochemistry demonstrated expression of
the B-cell antigens CD20 and CD79a by the majority of the lym-
phoid cells, with abundant small reactive T-cells (CD2-positive,
CD3-positive, CD5-positive and CD43-positive). There were small
numbers of lgD and CD23-positive B-cells consistent with residual
mantle zone cells. Larger numbers of Bcl-6-positive cells are identi-
ﬁedwithin the germinal centres but these germinal centre cells are
Bcl-2-negative. The Ki67 proliferative fraction is high within the
reactive germinal centre fragments. The appearances conﬁrmed
B-cell, mature, extra nodal marginal zone lymphoma of mucosal
associated lymphoid tissue (MALT). Immunohistochemistry on the
wedge biopsy of the lesion on the arm showed expression of the
B-cell antigens CD20 and CD79a by the neoplastic cells, in keeping
with diffuse large B cell lymphoma which might represent a high
grade transformation of the breast lymphoma. Staging CT and PET
CT showed involvement of a right axillary node (3.3 cm) and bone
marrow examination showed no inﬁltration.
She has since had 4 cycles of R-CHOP chemotherapy is due for
a repeat CT to assess interval progress, with a view to complete
2 further cycles and stop treatment if a ﬁnal CT and PET show
response.
2.4. Review of literature
Malignant lymphomas primarily arising in the breast and in the
absence of previously detected lymphoma localizations are termed
‘primary breast lymphomas’ (PBLs) [5]. PBL accounts for less than
0.5% of breast malignancies [6]. The PBL incidence is 0.04–0.53%
of all primary malignant tumours of the breast and 2.2% of extra
nodal lymphomas [5]. The most common presentation of PBL is
with an incidental breastmass [7,8]. On histology,majority of these
are diffuse large B cell lymphoma (DLBCL) with other PBL of low
grade histology i.e. follicular lymphoma or extra nodal marginal
zone (MALT) lymphoma being rarer [6]. In a series of 37 patients
with lymphoma involving the breast at initial presentation, 49%
were DLBCL, followed by follicular and MALT representing a com-
bined 38% [7]. Likewise in a Swiss series, 5 out of 7 patient with
primary breast lymphoma had DLBCL, one follicular and one a
MALT lymphoma [8]. These PBL of low grade histology has been
further investigated by the International extra nodal lymphoma
study group which studied 60 patients (36 follicular and 24 MALT)
[7] most presented with Ann Arbor stage Ie of IIe except for IVE
in 3 patients due to bilateral breast involvement, found on imag-
ing and conﬁrmed on cytology. Only 2 of the 60 presented with
B-symptoms [6].
Current treatment of DLBCL following tissue diagnosis is with
RCHOP based chemotherapy alone or with radiotherapy. Ganjoo
et al. [7] reported a 5 year progression free survival rate of 61% and
5 year overall survival of 82%. In a French series [9] of 19 patients
(17 DLBCL, 2 follicular/diffuse grade 3 lymphomas), four patients
received local treatment only (resection and local radiotherapy)
while the remaining 15 received chemotherapy (CHOP or ACVBP
followed by involved ﬁeld radiotherapy). Three of the four patients
treated with local treatment only died of their lymphomas. Among
the 11 treated with CHOP, 2 died of their lymphomas. The role of
CNS prophylaxis remains unclear as rates of CNS involvements are
low. The IELSG series demonstrated a similar behaviour of MALT
PBL with primary extra nodal MALT in other locations. However
patients with follicular PBL had worse progression-free survival
(PFS) and overall survival (OS) compared to limited stage nodal
follicular in other locations, suggesting an adverse prognostic role
of primary breast localisation [6]. In the Swiss series, of all PBL,
ﬁve and ten year survivals were 57% and 17%, respectively. In the
3 patients who died, 2 had tumours that was Bcl-2 positive but
Bcl-6 negative. All surviving patients have positive Bcl-2 and Bcl-6
immunostaining. This may represent important prognostic factors
if proven in a larger study [8].
The role of surgery in this disease should be limited to get a
deﬁnitive diagnosis [10,11]. While for the staging and the treat-
ment CT scan and chemo radiotherapy are, respectively,mandatory
[12,13]. Nowadays, surgical resection plays a therapeutic role only
in MALT lymphomas, whereas for large B cell lymphomas has only
a diagnostic indication. For such disease, the cornerstone of treat-
ment is systemic chemotherapy [12].
3. Ovarian cancer metastasizing to breast
3.1. Case report
This is an 86 year old lady with known ovarian serous papil-
lary carcinoma of the ovary for which she had undergone total
abdominal hysterectomyandbilateral salpingo-oophorectomyand
omentectomy a year ago. This was followed by chemotherapy in
the form of 6 cycles of Carboplatin. She presented with a lump
in her right axilla. On examination there was a 3×3 cm lump in
the right axilla. Mammogram showed a 30mm pathological node
and FNA was reported as C5, metastatic in nature. Needle frag-
ment from lymphnode revealed poorly differentiated carcinoma. A
core biopsy of the node showed features consistentwithmetastatic
poorly differentiated serous papillary carcinoma of ovarian or pri-
mary peritoneal origin. Tumour expressed pancytokeratins and
cytokeratin 7 but not cytokeratin 20. Staining for CA125 showed
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Fig. 2. Immunohistochemistry of metastatic poorly differentiated serous papillary
carcinoma.
strong uniform staining for WT1 and P53. Staining for CEA, TTF1
and BRST-2 was found to be negative. A staging CT abdomen and
pelvis conﬁrmed disease recurrence Figs. 2 and 3.
Treatment: Shewent on to receive chemotherapy in the form of
Carboplatin and Paclitaxel, the latter was omitted after 1 cycle due
to development of neuropathy and lethargy. She completed 6 cycle
of Carboplatin given every 3 weeks. She initially responded to the
treatment and this was conﬁrmed on the follow up CT.
Unfortunately she had a relapse of the condition after a few
months, and was not offered any further treatment due to her
frailty. She passed away within 2 years of the initial diagnosis of
her axillary metastasis.
3.2. Review of literature
Supradiaphragmatic metastases from ovarian cancer account
for less than 1% of all breast malignancies with the most com-
mon type being of serous carcinoma. In one paper themajority had
evidence of extra mammary malignancy on discovery the breast
metastases. Of these cases only 1 out of 32 cases involved pri-
mary ovarian carcinoma [14]. Although it is very rare Yamasaki
et al. [15] reported 30 cases of ovarianmalignancymetastatic to the
breast. Recine et al. [16] studied a series of 18 patients with metas-
tases to breast of which 14 from serous ovarian carcinomas and 4
Fig. 3. Staining of WT1 for CA 125.
peritoneal serous carcinomas. The metastases were discovered on
average 20 months post presentation with high grade serous car-
cinomas. These ﬁndings are similar to those published previously
suggesting most breast metastases of ovarian origin usually occurs
with knownpreviousmalignancy. Of Recine et al., therewere also 3
cases presenting as stage IV having synchronous breast and axillary
lymph node metastases. Susini et al. [17] presented a case of ovar-
ian carcinoma detected at screeningmammogram initially thought
to be intramammary lymph node metastases. The patient had a CA
125 within normal limits but histology following quadrantectomy
and axillary dissection suggested that this may have ovarian ori-
gin. PET scan showed a small simple ovarian cyst with high FDG
uptake which showed turned out to be serous ovarian carcinoma
microscopically. As such accurate histology may change manage-
ment course for the patient. In a separate study by Ozsaran et al.
[18], the ovarian cancer metastases to both breasts and axillary
lymph nodes. The patient presented with large pelvic mass and
pleural effusion. Initial breast examinationandmammogramswere
normal but even with chemotherapy and radiotherapy went on to
have bilateral swelling of the areolas, developed nipple retraction
and mammogram at that point revealed multiple areas of calciﬁ-
cation. This highlights the need for serial examination for breast
disease in this group. It is important that metastasis to the breast
be differentiated accurately from primary breast cancer, because
prognosis and treatment differ signiﬁcantly [18,19].
4. Primary osteosarcoma of the breast
4.1. Case report
An 81 year old lady presented with a lump in her right breast.
On examination there was a suspicious 3×2 cm lump on the right
breast. This corresponded to a 34mm irregular mass with micro
calciﬁcation on mammography. FNA was reported as C5 and core
biopsy showed it to be suspicious of either sarcoma or metapla-
sia. She underwent a right mastectomy. The histopathology report
showed that the tumour dimensions were of 30×20×20mm.
It appeared well circumscribed, relatively uniform with central
necrosis. It comprised of osteoid multinucleate giant cells and
abundant undifferentiated stroma. There was no evidence of any
epithelial component and staining for cytokeratins like 34beta12E
and MNF16 were negative. The tumour was also negative for
smoothmuscle actin. The stromal componentwas strongly positive
for vimentin. There was no vessel space invasion.
Excisionwas completebyamarginof at least 20mm.Therewere
no features suggesting any antecedent phyllodes tumour (Fig. 3).
The dissected right axillary lymph nodes showed reactive features
only, with no evidence of metastatic carcinoma. Overall, the histo-
logical featureswere those of a Primary Breast Osteosarcoma (PBO)
with tumour diameter 35mm, no vessel space invasion and lymph
node negative. She went on to have radiotherapy and at 5 years
there had been no evidence of local recurrence. This case has been
reported in literature Fig. 4 [20].
4.2. Review of literature
The literature suggests less than 0.1% of breast malignancies are
due to primary sarcoma. However ‘pure osteosarcoma’ that has no
epithelial component, not arising from bone and not associated
with a benign tumour is rare. This is less than 1% of all soft tis-
sue sarcomas and tends appear in the more elderly compare to
skeletal osteosarcomas [21]. The Mayo clinic series over 60 years
[22] had 24 of 25 patients with primary breast sarcoma which pre-
sented with a palpable mass, of which 1 was an osteosarcoma.
Coussy et al. [21] described the case of a 61 year old woman who
CASE REPORT – OPEN ACCESS
14 C.E. Ng et al. / International Journal of Surgery Case Reports 11 (2015) 11–17
Fig. 4. Slide rich with osteoid multinucleate giant cells and abundant undifferenti-
ated stroma which is positive for vimentin.
presented with a painless mass which turned out to be osteosar-
coma. The mammogram showed a well-deﬁned mass with large
macro calciﬁcation closely resembling bone as well as peripheral
soft tissue mass. An MRI showed low signal intensity of the cen-
tral mineralised matrix with rapid enhancement of the peripheral
mass. The core biopsy conﬁrmed a spindle shaped tumour. Simi-
larly a Japanese case of a 59 year old woman who presented with a
left breast lump described mammography which showed crushed
stone like calciﬁcation. Immunohistochemistry indicated the pres-
ence of vimentin without epithelial markers [23]. The diagnostic
criteria for osteosarcoma is the absence of epithelial component in
the tissue with neoplastic osteoid element [20,24–28].
Recommended management includes total excision with ade-
quate margins but no axillary dissection is required as lymph node
involvement is rare and no radiotherapy is required either [21–23].
Treatment is poorly standardised but adjuvant chemotherapy
should be considered for patients based on tumour size, histolog-
ical grade, and histological subtype, with inﬁltrative margins and
necrosis as poorprognostic features. The author [22,23] also summ-
arised that tumour size appeared to be a more valuable prognostic
factor for survival rates.
5. Metaplastic carcinomas
5.1. Case report of spindle cell carcinoma
A 58 year old lady presented with a lump in her left breast.
She had previously undergone excision of a benign breast lump
left breast 10 years ago. On examination there was some indura-
tion at the existing scar butmammogram showed 2 new suspicious
masses associated to the lumpectomy site. FNA was reported as C5
and core biopsy showed an invasive metaplastic carcinoma with
focal hyalinisation of the stroma. It expressed epithelial mark-
ers cytokeratin (KAE1/3 and MNF116) and E cadherin indicating
a spindle cell carcinoma which was ER, PGR and HER2 negative
Figs. 5 and 6.
Treatment: She underwent mastectomy and sentinel lymph
node followed by adjuvant chemotherapy in the form of 6 courses
of FEC to which she responded very well. This lady developed
metastatic recurrence of her breast cancer in left upper lobe of lung
after one year andunderwent surgical excision of it. A repeat CT in 3
months’ time revealed a new left lower lobe nodule, but there was
no evidence of liver or bonymetastasis. She is currently undergoing
palliative chemotherapy in the form of Paclitaxel and Avastin.
Fig. 5. Staining for CK epithelial marker.
5.2. Case report of invasive squamous cell carcinoma
A 74 year lady presented to the symptomatic breast clinic with
left nipple inversion associated with a subareolar mass. Her left
breast mammogram revealed a 20mm ill-deﬁnedmass highly sus-
picious of malignancy. She underwent a FNA of the lump, this
conﬁrmedmalignant cytologyC5.Acorebiopsyof the lumpshowed
a moderately/poorly differentiated squamous cell carcinoma with
central cystic andnecrotic element. Sheopted for amastectomyand
sentinel node biopsy. This conﬁrmed as invasive squamous cell car-
cinoma with no vessel space or skin involvement. The tumour was
ERandHER2negative. Therewasnoevidenceofnodal involvement.
No other treatment was offered and she is still under yearly
follow up for last 2 years Fig. 7.
5.3. Review of literature
Metaplastic carcinomas of the breast form a heterogeneous
group composing of epithelial or mesenchymal cell population
admixed with adenocarcinoma and include epithelial only car-
cinomas as a subtype [29]. This includes biphasic epithelial and
sarcomatoid carcinoma and monophasic spindle cell carcinoma
[30]. The group still represents less than 1% of all breast malig-
nancies and low grade disease can mimic benign ﬁbrous breast
lesions. Most metaplastic carcinomas are sporadic, but there may
Fig. 6. Staining for E cadherin.
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Fig. 7. Histology demonstrating squamous cell carcinoma of the breast.
be a slight propensity formetaplastic spindle cell carcinoma to arise
from pre-existing lesions, including papillomas, complex scleros-
ing lesions andnipple adenomas [30–32]. A series byAbd el-All [33]
of eight patients initially had FNAC deﬁne 4 as benign, 2 as suspi-
cious and 3 as malignant but following wide excision biopsy were
reclassiﬁed into 5 benign and 3malignant. The common ﬁnding on
FNAC was the presence of spindle cells without ductal epithelial
cells. Immunohistochemistry was helpful in clinching the diag-
nosis. According to Tse et al. [30] of the 34 sporadic carcinomas
identiﬁed in his series, oestrogen and progesterone receptors were
only positive in 4 (12%) and 3 (9%) of the cases, respectively. Like-
wise only 5 (15%) had positive expression of C-erbB2 oncogene,
whichmay limit oncological treatment options. Increasingly this is
referred to as triple-negative breast cancer (TNBC). Similarly, in a
series of 26 Canadian cases, only 5 were ER positive and 2 were PR
positive and 1 was HER2/neu positive adenosquamous carcinoma
[29].
Another variant seen is squamous cell carcinoma (SCC) of the
breast.Not tobe confusedwith themore commonly seen cutaneous
squamous cell carcinoma, the diagnosis of these breast lesions con-
stitutes less than 0.1% of all breast carcinomas [34]. SCC of the
breast, account for less than 1% of invasive carcinoma [35] and
nodal involvement varies from 6–50% depending on source and
use of chemotherapy is unclear. In the literature only some small
series are reported [36–39]. It does not involve skin or have asso-
ciated lesion on a second site [36]. Squamous cell metaplasia is
also seen in cysts, chronic inﬂammations, abscesses and adenoﬁ-
bromas [36,38]. This hypothesis is further supported bymany cases
where primary squamous cell carcinoma is reported after its initial
appearance as a benign disorder (abscess or after implantation of a
breast prosthesis or after radiation therapy) [38–43]. In the study
by Talmor et al. [43], it has been postulated that the origin of the
epithelial element could be from the epidermoid cysts deposited
during development or due to trauma or during surgery. Like other
metaplastic carcinoma they poorly respond to chemotherapy and
are an aggressive malignancy with poor outcomes [34].
6. Adenoid cystic carcinoma
6.1. Case reports 1
A 66 year old lady presented with a small lump in her right
breast. She had a previous breast cyst and a family history of breast
cancer (mother). Her mammogram conﬁrmed highly suspicious
lesion in her right breast. FNA was C3 but core biopsy conﬁrmed
this to be adenoid cystic carcinoma B5b. She underwent a wide
Fig. 8. Specimen demonstrating glandular lumens with eosinophilic material.
local excision and sentinel lymphnodebiopsy.Histology conﬁrmed
an 18×15×20mm tumour which was moderately differentiated
adenoid cystic carcinoma. It was well circumscribed and focally
encapsulated tumour. It composedof small basaloid cells and larger
cells with vesicular nuclei. Tumour cells were arranged in cribri-
form pattern but tubular and solid patterns were also noted. Most
lumina contained mucin but focally pink hyaline like material was
also present. Tumour was ER & PGR and HER 2 negative. There was
no lymphovascular or perineural invasion. No lymph node involve-
ment in sampling of axillary nodes was found.
She underwent radiotherapy treatment using standard tangen-
tial ﬁeld arrangement, 6-15MV photons, treating to a dose of 45Gy
in 20 fractions followed by boost to tumour bed right lateral breast
using single ﬁeld 12MeV electrons to a dose of 10Gy in 5 fractions.
55Gy in25 fractions to the tumourbed inviewofadenoidcystichis-
tology. There has been no evidence of local recurrence after 5 years
of surgery and she has been discharged from surveillance of breast
cancer. This case has been reported in literature by Veeratterapillay
et al. [44].
6.2. Case reports 2
An 82yr demented lady was found to have a right sided breast
lump by her carer for nearly 2 weeks. On examination there was a
ﬁrm lump palpable in the upper outer right breast and this was
conﬁrmed on USS. She refused to undergo a mammogram. She
had a core biopsy of the lump conﬁrming an adenoid cystic car-
cinoma. She underwent right mastectomy and axillary dissection.
The histology of the breast and axillary specimen showed a 21mm
well circumscribed adenoid cystic carcinoma. There were predom-
inantly cells with basaloid appearance with crowded monotonous
oval nuclei and only minimal cytoplasm. There was also cribriform
arrangement with well circumscribed pseudo lumens containing
myxoid material as well as very occasional true glandular lumens
containingdense eosinophilicmaterial. In other areas the cells form
elongated trabeculae and occasional tubules. None of the nodes
were involved and tumour was ER and HER2 negative Fig. 8.
She has been discharged from follow up due to her noncompli-
ance with surveillance or clinical examination, but last follows up
after 2 years had shown no recurrence.
6.3. Review of literature
ACC of the breast accounts for less than 0.1% of breastmalignan-
cies. ACC ismost commonly seen as a tumour of the salivary glands
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but there are similarities in morphology even though they behave
differently. The biggest study onACC is the population based cohort
study by Ghabach et al. [45] This showed no evidence of increase
risk of contralateral malignancy compared to the 60% signiﬁcantly
increased risk of contralateral breast cancer reported in the SEER-
based study [46]. Due to the rarity of this condition no deﬁnite
surgical treatment is recommended. There are studies supporting
simple lumpectomy with or without radiation, simple to radical to
mastectomy [47]. The chance of local recurrence has been high.
As such if lumpectomy [47,48] is preferred radiotherapy to the
breast is usually recommended. Some studies discourage perform-
ing any form of axillary surgery as the risk of nodal involvement
is minimal [47,49]. However, unlike its head and neck counterpart
it is associated with favourable prognosis with excellent survival
in the absence of other cancers [47]. Studies have shown it to be
low grade, node negative and receptor negative tumour [49] and
one of the only triple negative cancers where there is no role for
chemotherapy [50]. Although, lymph node involvement in breast
ACC is uncommon [45,47,51], some surgeons still prefer to per-
form sampling of nodes as seen in both our cases. As this condition
is rare, we are unable to not recommend axillary procedures due
to the diversity of procedures offered.
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